April 2017

New Product - Lenvima

Lenvima (lenvatinib mesilate) is a multiple receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3 and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET. Lenvima is indicated for the treatment of progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer. Lenvima is available as 4 mg and 10 mg capsules in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au